[The Impact of CD4+/CD8+ Ratio on the Efficacy of CAR-T Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma].

OBJECTIVE: ratio immediately prior to chimeric antigen receptor T-cell (CAR-T) infusion (Day 0) for treatment efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). METHODS: ratio and treatment efficacy was evaluated. RESULTS: =0.003) compared to those with a ratio <1. CONCLUSION: ratio ≥1 immediately prior to CAR-T infusion can predict a higher CAR-T treatment response rate and superior survival outcomes in R/R DLBCL patients.